[go: up one dir, main page]

MX2018002449A - FORMULATIONS OF DELAYED RELEASE, METHODS OF MANUFACTURING AND USE OF THE SAME. - Google Patents

FORMULATIONS OF DELAYED RELEASE, METHODS OF MANUFACTURING AND USE OF THE SAME.

Info

Publication number
MX2018002449A
MX2018002449A MX2018002449A MX2018002449A MX2018002449A MX 2018002449 A MX2018002449 A MX 2018002449A MX 2018002449 A MX2018002449 A MX 2018002449A MX 2018002449 A MX2018002449 A MX 2018002449A MX 2018002449 A MX2018002449 A MX 2018002449A
Authority
MX
Mexico
Prior art keywords
manufacturing
delayed release
mixture
methods
formulations
Prior art date
Application number
MX2018002449A
Other languages
Spanish (es)
Inventor
A Dill David
Original Assignee
Wellesley Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/842,539 external-priority patent/US10278925B2/en
Application filed by Wellesley Pharmaceuticals Llc filed Critical Wellesley Pharmaceuticals Llc
Publication of MX2018002449A publication Critical patent/MX2018002449A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones para reducir la frecuencia de micciones y métodos para fabricar las composiciones. Un método de fabricación incluye los pasos de formar una primera mezcla que comprende un primer ingrediente activo que comprende uno o más analgésicos, que recubren la primera mezcla con un primer recubrimiento de liberación retardada para formar un primer componente, formar una segunda mezcla que comprende un segundo ingrediente activo que comprende uno o más agentes analgésicos, recubrir la segunda mezcla con un segundo recubrimiento de liberación retardada para formar un segundo componente, y combinar el primer componente con el segundo componente para formar una tercera mezcla.Compositions to reduce the frequency of urination and methods for manufacturing the compositions are described. A manufacturing method includes the steps of forming a first mixture comprising a first active ingredient comprising one or more analgesics, which coat the first mixture with a first delayed release coating to form a first component, forming a second mixture comprising a Second active ingredient comprising one or more analgesic agents, coating the second mixture with a second delayed release coating to form a second component, and combining the first component with the second component to form a third mixture.

MX2018002449A 2015-09-01 2016-07-07 FORMULATIONS OF DELAYED RELEASE, METHODS OF MANUFACTURING AND USE OF THE SAME. MX2018002449A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/842,539 US10278925B2 (en) 2012-01-04 2015-09-01 Delayed-release formulations, methods of making and use thereof
PCT/US2016/041354 WO2017039833A1 (en) 2015-09-01 2016-07-07 Delayed-release formulations, methods of making and use thereof

Publications (1)

Publication Number Publication Date
MX2018002449A true MX2018002449A (en) 2018-08-24

Family

ID=58188685

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002449A MX2018002449A (en) 2015-09-01 2016-07-07 FORMULATIONS OF DELAYED RELEASE, METHODS OF MANUFACTURING AND USE OF THE SAME.

Country Status (10)

Country Link
EP (1) EP3344241A4 (en)
JP (1) JP2018526442A (en)
KR (1) KR20180054656A (en)
CN (1) CN108348487A (en)
AU (1) AU2016317093A1 (en)
HK (1) HK1259196A1 (en)
MX (1) MX2018002449A (en)
RU (1) RU2018111401A (en)
SG (1) SG11201805812QA (en)
WO (1) WO2017039833A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004093864A1 (en) * 2003-03-21 2004-11-04 Mcneil-Ppc, Inc. Non-steroidal anti-inflammatory drug dosing regimen
US9415048B2 (en) * 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20120237574A1 (en) * 2010-07-08 2012-09-20 Wellesley Pharmaceuticals, Llc Delayed-release formulation for reducing the frequency of urination and method of use thereof
US20150010599A1 (en) * 2010-07-08 2015-01-08 WELLESLEY PHARMACELJTlCALS, LLC Pharmaceutical formulation for reducing bladder spasms and method of use thereof
CN103191430A (en) * 2012-01-04 2013-07-10 韦尔斯利医药有限公司 Sustained-release formulation for alleviating urinary frequency and method of use thereof
SG11201500410XA (en) * 2012-01-04 2015-04-29 Wellesley Pharmaceuticals Llc Delayed-release formulation for reducing the frequency of urination and method of use thereof
BR112014016661A8 (en) * 2012-01-04 2017-07-04 Wellesley Pharmaceuticals Llc prolonged release formulation to reduce urination frequency and method of use

Also Published As

Publication number Publication date
WO2017039833A1 (en) 2017-03-09
SG11201805812QA (en) 2018-08-30
RU2018111401A (en) 2019-10-02
HK1259196A1 (en) 2019-11-29
AU2016317093A1 (en) 2018-04-26
CN108348487A (en) 2018-07-31
EP3344241A4 (en) 2019-04-03
EP3344241A1 (en) 2018-07-11
JP2018526442A (en) 2018-09-13
KR20180054656A (en) 2018-05-24

Similar Documents

Publication Publication Date Title
ECSP19051352A (en) JAK1 SELECTIVE INHIBITORS
MX2018012486A (en) Compositions for topical application of compounds.
CL2017000902A1 (en) Ror-gamma inhibitor dihydropyrrolopyridines
CL2015002860A1 (en) Alpha-v-beta-6 integrin antagonists
CO2017001994A2 (en) Active compounds towards bromodomains
ES2933249R1 (en) Compositions for the controlled release of active ingredients and methods of preparation thereof
EA201891225A1 (en) FILM FORM FOR LOCAL APPLICATION
MX2019003945A (en) CRYSTALLINE AND SALT FORMS OF PPAR AGONIST COMPOUNDS.
CL2017001923A1 (en) 9h-pyrrolo-dipyridine derivatives
CR20170077A (en) OPTIONALLY CONDENSED HEREROCICLYL PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOINMUNITY DISEASES
MX381735B (en) SOLID ORAL FORMULATION CONTAINING IRINOTECAN AND METHOD OF PREPARING SAME.
CO2020007895A2 (en) Histone acetyltransferase inhibitors of the myst family
MX2018002416A (en) DERIVATIVES OF 1,7-DIARIL-1,6-HEPTADIEN-3,5-DIONA, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME.
MX2016009225A (en) COMPOSITIONS IN THE FORM OF A SUSPENSION MODIFIED TO FORM CHROME COATINGS DIFFUSION.
CL2019002986A1 (en) New solid crystalline compound 3-phenyl-4-propyl-1- (pyridin-2-yl) -1h-pyrazol-5-ol hydrochloride.
BR112018074655A2 (en) fosnetupitant injectable formulation and method of manufacturing a formulation
EP3490530A4 (en) Slow release composition of active ingredients
AR108616A1 (en) COMBINED FORMULATION OF THREE ANTIVIRAL COMPOUNDS
GT201300225A (en) TIENO (2,3-D) DERIVED FROM PIRIMIDINE AND ITS USE FOR THE TREATMENT OF ARRITMIA
EA201890896A1 (en) SOLID PREPARATION FOR ORAL APPLICATION CONTAINING AMORPHOUS SOLIPHENACIN, AND A METHOD FOR ITS OBTAINING
CL2018002200A1 (en) Combined administration of a penetrating agent and a sulfur compound containing compound for plants.
MX2021000769A (en) Pharmaceutical composition containing clomipramine and preparation method therefor.
MX2018002449A (en) FORMULATIONS OF DELAYED RELEASE, METHODS OF MANUFACTURING AND USE OF THE SAME.
MX2018002450A (en) FORMULATION OF EXTENDED, DELAYED AND IMMEDIATE RELEASE, METHOD OF MANUFACTURE AND USE OF THE SAME.
MX389811B (en) COMPOSITIONS AND THEIR USE FOR THE TREATMENT OR PREVENTION OF ROSACEA